These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 33928568)
41. Nucleic Acid Therapeutics in Huntington's Disease. Singh K; Roy I Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088 [TBL] [Abstract][Full Text] [Related]
42. Preparation of Lipid-Conjugated siRNA Oligonucleotides for Enhanced Gene Inhibition in Mammalian Cells. Grijalvo S; Ocampo SM; Perales JC; Eritja R Methods Mol Biol; 2021; 2282():119-136. PubMed ID: 33928573 [TBL] [Abstract][Full Text] [Related]
43. Aptamer-siRNA chimeras for HIV. Takahashi M; Burnett JC; Rossi JJ Adv Exp Med Biol; 2015; 848():211-34. PubMed ID: 25757623 [TBL] [Abstract][Full Text] [Related]
44. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy. Li X; Zhao Q; Qiu L J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885 [TBL] [Abstract][Full Text] [Related]
45. siRNA Design and Delivery Based on Carbon Nanotubes. Li D; Al-Jamal KT Methods Mol Biol; 2021; 2282():181-193. PubMed ID: 33928577 [TBL] [Abstract][Full Text] [Related]
46. Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system. Wei J; Song R; Sabbagh A; Marisetty A; Shukla N; Fang D; Najem H; Ott M; Long J; Zhai L; Lesniak MS; James CD; Platanias L; Curran M; Heimberger AB Oncoimmunology; 2022; 11(1):2062827. PubMed ID: 35433114 [TBL] [Abstract][Full Text] [Related]
47. Advances in aptamer-mediated targeted delivery system for cancer treatment. He S; Du Y; Tao H; Duan H Int J Biol Macromol; 2023 May; 238():124173. PubMed ID: 36965552 [TBL] [Abstract][Full Text] [Related]
48. The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses. Ciccone G; Ibba ML; Coppola G; Catuogno S; Esposito CL Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047090 [TBL] [Abstract][Full Text] [Related]
49. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC. Wang H; Tao Z; Feng M; Li X; Deng Z; Zhao G; Yin H; Pan T; Chen G; Feng Z; Li Y; Zhou Y Biochem Biophys Res Commun; 2020 Dec; 533(3):368-375. PubMed ID: 32962858 [TBL] [Abstract][Full Text] [Related]
50. Aptamer-Targeted Attenuation of IL-2 Signaling in CD8 Rajagopalan A; Berezhnoy A; Schrand B; Puplampu-Dove Y; Gilboa E Mol Ther; 2017 Jan; 25(1):54-61. PubMed ID: 28129128 [TBL] [Abstract][Full Text] [Related]
51. Engineering of Solid Dosage Forms of siRNA-Loaded Lipidoid-Polymer Hybrid Nanoparticles Using a Quality-by-Design Approach. Lokras A; Foged C; Thakur A Methods Mol Biol; 2021; 2282():137-157. PubMed ID: 33928574 [TBL] [Abstract][Full Text] [Related]
53. What are the key targeted delivery technologies of siRNA now? Sioud M Methods Mol Biol; 2010; 629():93-107. PubMed ID: 20387145 [TBL] [Abstract][Full Text] [Related]
54. Aptamer-targeted delivery of Bcl-xL shRNA using alkyl modified PAMAM dendrimers into lung cancer cells. Ayatollahi S; Salmasi Z; Hashemi M; Askarian S; Oskuee RK; Abnous K; Ramezani M Int J Biochem Cell Biol; 2017 Nov; 92():210-217. PubMed ID: 29031805 [TBL] [Abstract][Full Text] [Related]
55. Aptamer-MiRNA Conjugates for Cancer Cell-Targeted Delivery. Esposito CL; Catuogno S; de Franciscis V Methods Mol Biol; 2016; 1364():197-208. PubMed ID: 26472452 [TBL] [Abstract][Full Text] [Related]
56. siRNA Vehicles for High Endosomal Escapability. Koide H; Yonezawa S; Asai T Methods Mol Biol; 2021; 2282():171-179. PubMed ID: 33928576 [TBL] [Abstract][Full Text] [Related]
57. Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. Ma Y; Kowolik CM; Swiderski PM; Kortylewski M; Yu H; Horne DA; Jove R; Caballero OL; Simpson AJ; Lee FT; Pillay V; Scott AM ACS Chem Biol; 2011 Sep; 6(9):962-70. PubMed ID: 21766840 [TBL] [Abstract][Full Text] [Related]